A phase I trial of dasatinib and osimertinib in TKI naïve patients with advanced EGFR-mutant non-small-cell lung cancer
Background Osimertinib is an effective first-line therapy option for EGFR-mutant NSCLC, but
virtually all patients develop resistance. CRIPTO, through Src activation, has been …
virtually all patients develop resistance. CRIPTO, through Src activation, has been …
[HTML][HTML] In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
ID Passos, D Papadimitriou, A Katsouda… - Cureus, 2023 - ncbi.nlm.nih.gov
Materials and methods TNBC cell lines were cultivated and treated with various
concentrations of docetaxel and dasatinib (5 nM to 100 nM). Cell death and apoptosis were …
concentrations of docetaxel and dasatinib (5 nM to 100 nM). Cell death and apoptosis were …
Case report: tyrosine kinase inhibitors induced lymphadenopathy in desmoid tumor patients
S Papadopoulos, P Koulouris… - Frontiers in …, 2022 - frontiersin.org
Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a
rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib …
rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib …
Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia
KI Zhou, C Lin, JL Neff, A Galal - BMJ Case Reports CP, 2023 - casereports.bmj.com
The tyrosine kinase inhibitor dasatinib is approved for the treatment of chronic myeloid
leukaemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia …
leukaemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia …
Hyperplasie lymphoïde folliculaire induite par la prise de dasatinib, une entité à connaître
M Phelippeau, C Lefebvre, MC Jacob, C Syrykh… - Annales de …, 2023 - Elsevier
Résumé L'hyperplasie folliculaire lymphoïde secondaire à la prise de dasatinib est
récemment décrite. Cette lésion est parfois difficile à différencier d'une prolifération …
récemment décrite. Cette lésion est parfois difficile à différencier d'une prolifération …
Reversible follicular lymphoid hyperplasia related with dasatinib: first case report from Turkey
AA Solmaz, HE Ozcan, AC Ugurludogan… - Journal of …, 2022 - Springer
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized
by the presence of a cytogenetic abnormality, the Philadelphia (Ph) chromosome. BCR-ABL …
by the presence of a cytogenetic abnormality, the Philadelphia (Ph) chromosome. BCR-ABL …
[PDF][PDF] Chronic myeloid leukaemia with generalized lymphadenopathy–a high risk category
WDD Prasanni, HSA Williams, YJ Costa… - 2022 - repository.kln.ac.lk
Chronic myeloid leukaemia (CML) presenting with generalized lymphadenopathy is an
uncommon manifestation of CML. Lymphadenopathy in these patients could be due to …
uncommon manifestation of CML. Lymphadenopathy in these patients could be due to …
Dasatinib 中止によりdasatinib-associated lymphadenopathy が改善した慢性骨髄性白血病
竹下陽介， 田中まりか， 白蓋万葉子， 安藤太基… - 臨床血液, 2022 - jstage.jst.go.jp
抄録 症例 1: 58 歳男性. 慢性骨髄性白血病 (CML) と診断後 dasatinib を開始し 13 ヶ月後に MR
4.5 に到達. 39 ヶ月後に dasatinib を休薬したが 42 ヶ月後に MMR を喪失したため dasatinib …
4.5 に到達. 39 ヶ月後に dasatinib を休薬したが 42 ヶ月後に MMR を喪失したため dasatinib …